Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Claudia Sommer, MD

University of Würzburg, Würzburg, Germany

9:35 MIN

CIDP

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

DOWNLOAD PDF

Incidence of GBS and CIDP Following Influenza Vaccination

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

25:18 MIN

CIDP
GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements

Jeffrey A. Allen, MD

University of Minnesota

12:15 MIN

CIDP

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

DOWNLOAD PDF

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

3:00 MIN

CIDP
MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF

NOW PLAYING

9:35

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

NOW PLAYING

25:18

Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

NOW PLAYING

12:15

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

NOW PLAYING

3:00

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Our Experts on CIDP

VIEW ALL EXPERTS

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

CIDP
GBS
MMN

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.

Van den Bergh, MD PhD

University Hospital Saint-Luc, Brussels, Belgium

Van den Bergh, MD PhD

University Hospital Saint-Luc, Brussels, Belgium

CIDP

Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Carol L. Koski, MD

GBS/CIDP Foundation International

Carol L. Koski, MD

GBS/CIDP Foundation International

CIDP
GBS

Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring